Discovery and Characterization of Diazenylaryl Sulfonic Acids as Inhibitors of Viral and Bacterial Neuraminidases by Anja Hoffmann et al.
ORIGINAL RESEARCH
published: 15 February 2017
doi: 10.3389/fmicb.2017.00205
Frontiers in Microbiology | www.frontiersin.org 1 February 2017 | Volume 8 | Article 205
Edited by:
Yuji Morita,
Aichi Gakuin University, Japan
Reviewed by:
Lilia Macovei,
The Forsyth Institute, USA
Dane Parker,
Columbia University, USA
Sunil D. Saroj,
Stockholm University, Sweden
*Correspondence:
Johannes Kirchmair
kirchmair@zbh.uni-hamburg.de
Specialty section:
This article was submitted to
Antimicrobials, Resistance and
Chemotherapy,
a section of the journal
Frontiers in Microbiology
Received: 16 November 2016
Accepted: 30 January 2017
Published: 15 February 2017
Citation:
Hoffmann A, Richter M,
von Grafenstein S, Walther E, Xu Z,
Schumann L, Grienke U, Mair CE,
Kramer C, Rollinger JM, Liedl KR,
Schmidtke M and Kirchmair J (2017)
Discovery and Characterization of
Diazenylaryl Sulfonic Acids as
Inhibitors of Viral and Bacterial
Neuraminidases.
Front. Microbiol. 8:205.
doi: 10.3389/fmicb.2017.00205
Discovery and Characterization of
Diazenylaryl Sulfonic Acids as
Inhibitors of Viral and Bacterial
Neuraminidases
Anja Hoffmann 1, Martina Richter 1, Susanne von Grafenstein 2, Elisabeth Walther 1,
Zhongli Xu 1, Lilia Schumann 1, Ulrike Grienke 3, Christina E. Mair 3, Christian Kramer 2,
Judith M. Rollinger 3, Klaus R. Liedl 2, Michaela Schmidtke 1 and Johannes Kirchmair 2, 4*
1Department of Virology and Antiviral Therapy, Jena University Hospital, Jena, Germany, 2Centre for Chemistry and
Biomedicine, Institute of General, Inorganic and Theoretical Chemistry, University of Innsbruck, Innsbruck, Austria,
3Department of Pharmacognosy, Faculty of Life Sciences, University of Vienna, Vienna, Austria, 4Center for Bioinformatics,
University of Hamburg, Hamburg, Germany
Viral neuraminidases are an established drug target to combat influenza. Severe
complications observed in influenza patients are primarily caused by secondary
infections with e.g., Streptococcus pneumoniae. These bacteria engage in a lethal
synergism with influenza A viruses (IAVs) and also express neuraminidases. Therefore,
inhibitors with dual activity on viral and bacterial neuraminidases are expected
to be advantageous for the treatment of influenza infections. Here we report on
the discovery and characterization of diazenylaryl sulfonic acids as dual inhibitors
of viral and Streptococcus pneumoniae neuraminidase. The initial hit came from
a virtual screening campaign for inhibitors of viral neuraminidases. For the most
active compound, 7-[2-[4-[2-[4-[2-(2-hydroxy-3,6-disulfo-1-naphthalenyl)diazenyl]-
2-methylphenyl]diazenyl]-2-methylphenyl]diazenyl]-1,3-naphthalenedisulfonic acid
(NSC65847; 1), the K i-values measured in a fluorescence-based assay were lower than
1.5 µM for both viral and pneumococcal neuraminidases. The compound also inhibited
N1 virus variants containing neuraminidase inhibitor resistance-conferring substitutions.
Via enzyme kinetics and nonlinear regression modeling, 1 was suggested to impair the
viral neuraminidases and pneumococcal neuraminidase with a mixed-type inhibition
mode. Given its antiviral and antipneumococcal activity, 1 was identified as a starting
point for the development of novel, dual-acting anti-infectives.
Keywords: influenza virus, Streptococcus pneumoniae, coinfection, neuraminidase, small molecule inhibitor,
diazenylaryl sulfonic acid
INTRODUCTION
Two of the major threats related to influenza A viruses (IAVs) are the genetic variability of
the virus, which can lead to drug resistance (Hurt, 2014), and the lethal synergistic relationship
(co-pathogenesis) that can form with bacteria, such as Streptococcus (S.) pneumoniae during
superinfection (McCullers, 2014). At present, viral neuraminidase (NA) is the primary target of
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medicines for the treatment of influenza but only few inhibitors
of this enzyme (NAIs) have been approved to date: oseltamivir,
zanamivir, laninamivir, and peramivir (Li et al., 2015). Mutations
of viral NA leading to drug resistance are often related to a
loss of viral fitness, which limits the emergence of NAI-resistant
strains (Abed et al., 2006; Ferraris and Lina, 2008; Nguyen
et al., 2012). However, resistant strains can develop suddenly if
compensatory mutations of NA enable efficient viral replication.
This was observed, e.g., for oseltamivir in the season 2007/08
(Meijer et al., 2009; Baz et al., 2010; Bloom et al., 2010). In 2009,
these oseltamivir-resistant seasonal H1N1 IAVs were succeeded
by multiple reassorted pandemic H1N1 IAVs [A (H1N1)pdm09]
(Hurt et al., 2009). These carry a NAI-sensitive NA gene of
European swine influenza viruses (Bauer et al., 2012; Duerrwald
et al., 2013), making them again susceptible to oseltamivir (Meijer
et al., 2009).
The lethal synergism between (IAVs) and S. pneumoniae,
which requires influenza virus prior to bacterial infection
(McCullers and Rehg, 2002), has a grave medical and economic
impact. Fatality rates for complicated bacterial pneumonia linked
to this co-pathogenesis remain high, despite advances in medical
care and the availability of a wide range of antibiotics as reviewed
by McCullers and English (2008). These, authors state that “...the
virus appears to worsen the clinical presentation, the tempo of
progression, and the host immune response to the pneumonia.”
They suggest that influenza viruses affect the pathogenesis and
response to therapy. The contribution of a number of viral factors
to the lethal synergism, in particular viral NA (McCullers and
Bartmess, 2003; Peltola and McCullers, 2004; McCullers, 2014;
Siegel et al., 2014), has been thoroughly investigated, whereas
studies of bacterial factors have emerged only more recently.
For example, we showed that influenza virus replication rates
can be enhanced in the presence of bacterial NA in an in
vitro model, and that inhibitors active against both viral and
bacterial NA (Xu et al., 2008; Gut et al., 2011; Walther et al.,
2015, 2016b; Grienke et al., 2016) can disrupt this synergism
(Walther et al., 2016b). Therefore, the research of compounds
with resistance-breaking capacity and dual activity on both viral
and bacterial NAs represent promising and important avenues
for the development of new anti-infective therapeutics.
Abbreviations: BHI, brain heart infusion; CPE, cytopathic effect; DAD,
diode array detector; DANA, 2,3-dehydro-2-deoxy-N-acetylneuraminic acid;
DEMEM, Dulbecco’s Modified Eagle Medium; DMSO, dimethyl sulfoxide;
DTP, Developmental Therapeutics Program; EMEM, Eagle’s minimum essential
medium; ESI, electrospray ionization interface; FC, fold change; FL, fluorescence;
HA, hemagglutination; HPLC, high performance liquid chromatography; IAV,
influenza A virus; IPTG, isopropyl β-D-1-thiogalactopyranoside; LC, liquid
chromatography; NA, neuraminidase; NanA, S. pneumoniae neuraminidase; NAI,
neuraminidase inhibitor; NCI, National Cancer Institute; NIH, National Institute
of Health; MD, molecular dynamics; MDCK, Madin-Darby canine kidney; MIC,
minimal inhibitory concentration; MOI, multiplicity of infection; MS, mass
spectrometry; MUNANA, 2′-(4-methylumbelliferyl)-α-D-N-acetylneuraminic
acid sodium salt hydrate; OD, optical density; PAINS, pan assay interference
compounds; PCR, polymerase chain reaction; PDB, Protein Data Bank; PFU,
plaque-forming unit; RFU, relative fluorescence unit; rNanA, Recombinant
S. pneumoniae neuraminidase; SD, standard deviation; TCID50, 50% tissue culture
infective dose; TLC, thin-layer chromatography; TSB, tryptic soy broth; vis, visible;
WT, wild type.
Computational approaches have been playing a key role in the
discovery and development of NAIs since the 1990’s (von Itzstein
et al., 1993). At that time, conformational flexibility of this target
protein was generally not taken into account during the design
of new inhibitors. Later the flexibility of NA received a lot of
attention because of its impact on the geometric and electrostatic
properties of the ligand binding site and hence on ligand binding.
First indications of the remarkable flexibility of influenza NA
came from crystal structures of group-1 NAs (N1, N4, N5, and
N8) derived under different soaking conditions (Russell et al.,
2006). It was found that the binding site-forming 150-loop of
group-1 NAs is able to exist in at least two stable conformations.
A more complete picture of the extent of this loop flexibility
was developed by Amaro et al. (2007, 2009) who observed
and characterized significant conformational shifts of the 150-
and 430-loops by molecular dynamics (MD) simulations. It was
suggested that this flexibility might also allow the binding of
structurally distinct and in particular bulkier compounds. More
recently, von Grafenstein et al. (2013) found that the dynamics of
NA and specifically of the 150-loop are influenced by assembly
states (i.e., viral NAs form homotetramers, while other NAs
are active as monomers). Woods et al. (2013) investigated the
unbinding and binding of oseltamivir using MD simulations,
which confirmed the key role of the 150-loop.
Since the discovery of the conformational flexibility of the
150-loop, a larger number of NAIs have been reported that are
thought or confirmed as binding to more open conformations of
the enzyme. First examples of such inhibitors came from Cheng
et al. (2008) who combinedmolecular dynamics (MD) simulation
techniques with ligand docking in order to take protein flexibility
into account during the virtual screening for NAIs. They
screened the diversity set of the National Cancer Institute’s (NCI)
Developmental Therapeutics Program (DTP)1 on an ensemble
of eight representative structures of N1, including an X-ray apo,
an X-ray holo, and six frames extracted from MD simulation
trajectories via clustering. In total, Cheng et al. (2008) selected
27 compounds, half of which would have been missed if only
the X-ray structures would have been used for virtual screening.
The activity of several of the compounds was detected with a
fluorescence-based assay (FL assay) (Amaro et al., 2009). Further
examples of small molecules that have been linked to binding to
the open enzyme conformation include novel sialic acid analogs
(Rudrawar et al., 2010; Adabala et al., 2013; Mohan et al., 2014)
and natural products (Grienke et al., 2010, 2016).
Inspired by the work of Cheng et al. (2008) who identified
inhibitors of viral NAs in the NCI DTP’s Diversity Set, we
extended this effort to screen the NCI DTP’s complete molecular
library with an ensemble-based virtual screening approach.
Candidate molecules were acquired and tested in vitro on
influenza and in addition on bacterial NA. Here we report on the
key outcome of this work, the discovery of diazenylaryl sulfonic
acids as dual inhibitors of influenza and S. pneumoniae NA.
1National Cancer Institute Developmental Therapeutics Program Diversity
Set. Available online at: https://dtp.cancer.gov/organization/dscb/obtaining/
available_plates.htm (Accessed Oct 26, 2016).
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MATERIALS AND METHODS
Virtual Screening
The complete molecular library of NCI’s DTP was downloaded
from the institute’s website2. The chemical structures were
processed with Pipeline Pilot Student Edition (version 6.1.5,
Accelrys, San Diego, CA): The “Organic Filter” and “Bad
Valence Filter” components were used to remove unwanted
molecules. A filter for the removal of potential pan assay
interference compounds (PAINS) (Baell andHolloway, 2010) was
not applied at that time to avoid loss of potentially interesting
compounds (Senger et al., 2016). However, during later stages
of the project, the RDKit PAINS 4 filter (Landrum, 2015) was
applied to flag potential PAINS. All molecules were ionized
at pH 6.5 using the “Ionize Molecule at pH” component
(default settings). The 3D structures were minimized using the
“Minimize Molecule” component (default settings). Docking of
the ∼134,000 compounds that passed all data processing steps
was conducted with GOLD version 4.0 (Jones et al., 1997). Two
X-ray structural models and 10 representative frames collected
from MD simulations served as receptors. The X-ray structures
were selected to represent the apo-structure (2hu0) and holo-
structure (2hty) of N1 (open X-ray conformation). Full atom,
explicit solventMD simulations with Amber 10 (Case et al., 2008)
were started from 2hty (chain B). The technical protocol of the
MD simulations and extraction of representative frames from the
MD trajectory is published in Grienke et al. (2010). In brief, 10
representative frames were selected for docking using a clustering
algorithm from the 20 ns production phase of a full-atom, explicit
solvent simulation.
The X-ray structural models were prepared for docking
with the GOLD protein preparation wizard (default settings).
Representative frames selected from the MD trajectories were
used for docking (all water molecules were removed). GoldScore
(part of the GOLD software package) was employed for scoring.
Three docking runs were performed for each ligand and each
protein conformation (with only the highest-ranked pose saved
for hit selection).
Compounds
The control compounds, oseltamivir carboxylate (GS4071;
GlaxoSmithKline, Uxbridge, UK), the sialic acid analog
2,3-dehydro-2-deoxy-N-acetylneuraminic acid (DANA; Sigma-
Aldrich, Deisenhofen, Germany) and imipenem (Sigma-Aldrich,
Steinheim, Germany) were dissolved in bi-distillated water
(10 mM). All test compounds were ordered from the NCI
(Bethesda, MD) and dissolved in dimethyl sulfoxide (DMSO;
Sigma Aldrich, Steinheim, Germany) to a final concentration
of 10 mM. The stock solutions of all compounds were stored
at 4◦C until use. The purity of all compounds was checked
by thin-layer chromatography (TLC) and high performance
liquid chromatography (HPLC)—diode-array detector (DAD)—
electrospray ionization interface (ESI)–mass spectrometry (MS)
and determined as>95% in all cases.
2National Cancer Institute Developmental Therapeutics Program
database. Available online at: http://dtp.nci.nih.,gov/docs/3d_database/
Structural_information/structural_data.html (Accessed Aug 24, 2009).
Thin-layer chromatography (TLC) parameters: Mobile phase
CH2Cl2-MeOH (3:1); stationary phase Merck silica gel 60 PF254;
detected with staining reagents vanillin/H2SO4 at visible light,
254 and 366 nm UV light. HPLC-MS was performed on an
Agilent 1100 s liquid chromatography (LC) system (Santa Clara,
CA, USA) hyphenated to a Bruker-Daltonics Esquire 3000
plus ion trap. LC parameters: Stationary phase Phenomenex
Hyperclone 5 µm C18 (150 × 3.0 mm); temperature: 40◦C;
mobile phase A = 80% water; B = 20% CH3CN; flow rate 1.0
mL/min; DAD detection wavelength: 210 nm; injection volume:
10 µL. Separations were performed by gradient elution (80/20
A/B in 15 min to 2/98 A/B) followed by a 5 min column wash
(2A/98B) and a re-equilibration period of 10 min. All chemicals
and solvents used were of analytical grade. MS parameters: Spray
voltage 4.5 kV; sheath gas N2, 30 psi; dry gas N2, 6 L/min, 350
◦C;
scanning range m/z 50–1500.
Cell Lines and Viruses
Madin-Darby canine kidney (MDCK) cells (Cat.no. RIE
328, Friedrich-Loeﬄer Institute, Riems, Germany) were
propagated as monolayer in Eagle’s minimum essential medium
(EMEM) supplemented with 10% fetal bovine serum (Life
technologies, Darmstadt, Germany), 1% non-essential amino
acids, 1 mM sodium pyruvate and 2 mM L-glutamine. Human
lung carcinoma cells (A549; Institute of Molecular Virology,
University of Munster, Germany) were grown in Dulbecco’s
Modified Eagle Medium (DMEM) supplemented with 10%
fetal calf serum (PAA Laboratories GmbH, Cölbe, Germany).
The HEK293 cell line (internal cell culture collection of the
Department of Virology and Antiviral Therapy, Jena University
Hospital, Jena) was cultured in serum-free EMEM supplemented
with 2 mM L-glutamine.
H1N1 influenza viruses A/Jena/5258/2009 (Jena/5258;
Kirchmair et al., 2011), A/Jena/8178/2009 (Jena/8178; Walther
et al., 2016b), reverse genetics generated A/WSN/1933 (WSN/33)
wild-type virus (Hoffmann et al., 2000) as well variants thereof
containing specific amino acid substitutions in NA (Schade et al.,
2015; Hoffmann et al., 2016), and the H3N2 influenza virus
A/Hong Kong/68 (HK/68; Schaper and Brümmer, Salzgitter,
Germany) were propagated on MDCK cells in serum-free
EMEM supplemented with 2 mM L-glutamine, 2 µg/mL trypsin,
and 0.1% sodium bicarbonate (test medium). Virus containing
supernatant was harvested after about 48 h of incubation at
37◦C, when the cytopathic effect (CPE) became microscopically
visible. Aliquots were stored at −80◦C until use. If not stated
otherwise, the media supplements were obtained from Lonza
Group Ltd. (Basel, Switzerland).
Propagation of Bacteria and Preparation of
Precipitated Pneumococcal Total Proteins
S. pneumoniae strain DSM20566 (serotype 1) was obtained
from the German Collection of Microorganisms and Cell
Cultures GmbH (Braunschweig, Germany). Bacteria were grown
on Columbia blood agar plates (BD Biosciences, Heidelberg,
Germany) at 37◦C in 5% CO2 overnight or cultured in brain
heart infusion (BHI) broth (Carl Roth GmbH + Co. KG,
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Karlsruhe, Germany) at 37◦C as described elsewhere (Walther
et al., 2015).
Precipitation of pneumococcal total proteins was described
previously (Richter et al., 2015). Briefly, 200µL of a pneumococci
culture (grown overnight in BHI broth) were precipitated by 1.8
mL of ice-cold absolute ethanol (−20◦C for 16 h). Aliquots were
centrifuged at 3000 × g for 20 min at 4◦C. The precipitate was
washed with 1 mL of ice-cold 70% ethanol. After centrifugation
at 3000 × g for 5 min at 4◦C, the supernatant was removed and
the pellet dried. The ethanol-precipitated proteins were dissolved
in 50 µL of NA assay buffer and stored at−20◦C until use.
Expression and Purification of
S. pneumoniae Neuraminidase Constructs
from Escherichia coli
Primers NA_116aaNdeI_fw (5′-TGCACGACATATGGAAAAT
GTC-3′) and NA_311aaNdeI_fw (5′-GTCAACATATGAAA
CGCTCAG-3′) were, respectively paired with NA_833aaXhoI_rv
(5′-ATTGAAGGGCTCGAGCCTTG-3′) to generate two
recombinant S. pneumoniae neuraminidase (NanA) variants
with shortened C-terminus, namely NanA-LC (representing
lectin and catalytic domains, residues 116–833) and NanA-CC
(representing catalytic center, residues 311–833) constructs
from individual S. pneumoniae strains DSM20566, CF8919,
and CJ9400 (Xu et al., 2016). Briefly, each NdeI/XhoI double-
digested polymerase chain reaction (PCR) product was ligated
to the Escherichia (E.) coli expression vector pET-28a (Novagen,
Merck KGaA, Darmstadt, Germany). The obtained plasmids
encoded a series of N-terminal 6xHis-tagged NanA peptides.
Transformation of E. coli was calcium chloride mediated. A 100
mL E. coli BL21(DE3) culture (Invitrogen life Technologies,
Thermo Fisher Scientific, Darmstadt, Germany) with the
plasmid was used to synthesize the enzyme. Gene expression
was induced by isopropyl β-D-1-thiogalactopyranoside (IPTG)
at a final concentration of 0.5 mM after a 4 h initial cultivation
at 37◦C. All enzymes were obtained from New England Biolabs
(Frankfurt amMain, Germany). The broth was further incubated
overnight at 25◦C before harvested by centrifugation. The cell
pellet was subjected to B-PER Protein Extraction Reagents
(Thermoscientific, Darmstadt, Germany) for lysis and protein
release. N-terminal His-tagged NanA was purified via HisPur
Cobalt Spin Column (Thermoscientific, Darmstadt, Germany)
and desalted by Pierce Concentrators PES 30K MWCO. The
protein sample was stored in a 50% glycerol solution at−20◦C.
NA Inhibition Analyses
Viral (whole virus) and bacterial NA activity as well as their
inhibition were measured by using a fluorescence (FL) assay with
the substrate 2′-(4-methylumbelliferyl)-α-D-N-acetylneuraminic
acid sodium salt hydrate (MUNANA, 100 µM; Sigma-Aldrich
GmbH, Taufkirchen, Germany), and/or a hemagglutination
(HA)-based NA inhibition assay (HA assay) with human
erythrocytes (Institute of Transfusion Medicine, University
Hospital Jena, Jena, Germany), both assays as published recently
(Richter et al., 2015). Recombinant NanA (rNanA) and total
precipitated bacterial protein of S. pneumoniae DSM20566 were
used in FL and HA assays. Interference of the compounds
with the FL signal (self-fluorescence and quenching) was
excluded as described previously (Richter et al., 2015). The
studied assay interference phenomena of test compounds
in the HA assay included lysis or hemagglutination of the
human erythrocytes by test compounds as well prevention
of virus-induced hemagglutination (Richter et al., 2015). Each
compound was tested at least three times in both NA inhibition
assays.
Enzyme Kinetics
The Michaelis constant (Km), and the inhibition constant (K i)
of NAIs were evaluated for WSN/33 variant NA-wt and rNanAs
in FL assays (Marathe et al., 2013; Xu et al., 2016). No
(control) or at least four inhibitor concentrations (as indicated
in Supplementary Figures 1, 2) were applied in combination with
four (NanA: 30, 60, 120, and 240 µM; viral NA: 15, 30, 60, and
120 µM) MUNANA substrate concentrations to determine the
Km and K i.
To study the inhibitory effect of NAIs on viral NA,
whole virus (WSN/33 NA-wt) and NAI dilutions (each 10
µL) were preincubated for 20 min at 37◦C or not pre-
incubated before the addition of 30 µL of MUNANA substrate
to see whether pre-incubation of NA with inhibitor affects
activity (Barrett et al., 2011; McKimm-Breschkin et al., 2013).
Relative fluorescence units (RFUs) correlating with the amount
of 4- methylumbelliferone, the resulting cleavage product of
MUNANA, were measured every 60 s for 60 min at 360/460
nm. In enzyme kinetics with rNanAs, RFU were measured
after 5 min of incubation at 37◦C. RFU were converted to
4-methylumbelliferone concentration in µM according to the
4-methylumbelliferone standard curve.
The Enzyme Kinetics Module of SigmaPlot 12.0 (Systat
Software, San Jose, CA) was applied to fit the calculated
velocity data (µM/min) to the Michaelis-Menten equation using
nonlinear regression and to determine the K i and Km values of
NAIs.
Cytotoxicity and Cytopathic Effect
Inhibition Assay
Cytotoxicity and CPE inhibition studies were performed on 2-
day-old confluent monolayers of MDCK cells grown in 96-well
plates as published (Schmidtke et al., 2001). Cytotoxicity was
analyzed 72 h after compound addition. In the CPE inhibition
assay, 50 µL of a serial half-log dilution of compound in test
medium (maximum concentration 100 µM) and a constant
multiplicity of infection (MOI: 0.003, 0.01, and 0.006 or 0.007
50% tissue culture infective dose (TCID50)/cell, for 8178/09,
WSN/33, and HK/68, respectively) of test virus in a volume of
50 µL of the test medium were added to cells. Then, plates
were incubated at 37◦C with 5% CO2 for 48 h. Crystal violet
staining and determination of the 50% cytotoxic (CC50) and
50% inhibitory concentration (IC50) was performed as described
earlier (Schmidtke et al., 2001). At least three independent assays
were conducted.
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Antibacterial Assays
The antibacterial activity of the compounds was investigated
using a microdilution assay in 96-well V-shape plates as well
as biofilm assay in flat-bottom plates with S. pneumoniae
DSM20566 as described earlier (Walther et al., 2015). Briefly,
after cultivation on Columbia blood agar plates with 5% sheep
blood at 37◦C in an atmosphere enriched with 5% CO2
overnight, bacteria were grown to mid-exponential growth phase
in BHI broth. For determination of bacterial growth and biofilm
inhibition, samples of precultured pneumococci were diluted
in BHI to match the turbidity of 1.5 × 108 colony forming
units (CFU) mL−1 (equivalent to a McFarland standard of 0.5).
The spectrophotometric measurement at 565 nm was performed
with a Den-1B McFarland densitometer (Grant Instruments,
Cambridge, England). For the microtiter broth microdilution
assay, untreated pneumococci in BHI (untreated control) or
pneumococci with serial compound dilutions (dilution factor
2; maximum tested concentration 50 µM) were incubated in
96-well V-shape plates (Greiner bio-one GmbH, Kremsmünster,
Austria) at 37◦C with 5% CO2 for 18 h. The planktonic growth of
untreated and compound-treated pneumococci was compared by
measuring optical density (OD) at 620 nm. The biofilm inhibition
assay was performed in 96-well F-bottom plates (Greiner bio-
one GmbH, Kremsmünster, Austria) with pneumococci diluted
in tryptic soy broth (TSB) for 2 h at 37◦C with 5% CO2. After
replacing the supernatant by TSB without (untreated control)
or with diluted compound (dilution factor 2; maximum tested
concentration 50 µM) and further 24 h of incubation, crystal
violet staining, dye elution, and OD measurement at 550 nm
were performed to quantify biofilm growth. In both antibacterial
assays, the mean OD of six untreated controls was set 100% and
used to calculate the 50% inhibitory concentration. At least three
independent assays were performed.
In order to test whether the antibacterial concentrations of
azo compounds exert a bactericidal or bacteriostatic activity, 100
µL of 1 and 2 (each 50 µM) were mixed with 50 µL bacteria
(106 cfu/mL S. pneumoniae DSM20566) in a 96-well V-shape
plate in two parallels and incubated for 18 h at 37◦C with 5%
CO2. Thereafter, 100 µL of suspension from each well was sub-
cultured on blood agar plates without test agent at 37◦C with
5% CO2 to predict whether ≥99.9% of the bacteria were killed
(i.e., a ≥3-log10 reduction in colony-forming units [cfu]/mL) on
subculture. If there were <150 cfu per plate, the compound was
rated bactericidal. In case of abundant bacterial growth (>150 cfu
per plate), the compound was rated bacteriostatic. The antibiotic
imipenem (Fitoussi et al., 1998; Walther et al., 2016a) served as
control compound and was tested as described in parallel.
Inhibitory Effect of Diazenylaryl Sulfonic
Acids on Viral Replication in the Absence
and Presence of Pneumococcal NA
The effect of 1 (NSC65847) on virus replication in the absence
and presence of rNanA of S. pneumoniae DSM20566 was
investigated in A549 cells at 10 µM concentration (Walther
et al., 2016b). The test medium contained DMEM, 0.5 µg/mL
trypsin and 1.3% bicarbonate. The supernatant was harvested for
determination of the inhibitory effect of test compounds on virus
yield by plaque assay 48 h p.i. Two assays with two parallels were
performed.
Modified Plaque Reduction Assay
The assay time and temperature conditions of the modified
plaque reduction assay were described recently (Makarov et al.,
2015). Here, confluent MDCK cell monolayers grown in 12-
well plates were inoculated with ∼30 pfu WSN/33 in 500 µL
test medium. Cells and/or virus were exposed to 1 (100 µM) or
oseltamivir (1 µM; for control) before infection, during the viral
adsorption phase, after adsorption phase or during the whole
replication cycle. Non-treated virus controls were included in all
assays. Three independent assays were performed.
Statistical Evaluation
Mean and standard deviation (SD) values were analyzed using
Microsoft Excel 2010. Statistically significant differences in K i
values and the NA inhibitory effect of A/WSN/1933 variants were
analyzed by Welch’s t-test (Microsoft Excel 2010).
RESULTS
Identification of Potential Inhibitors of Viral
NAs by Virtual Screening
An ensemble of 12 structural models of influenza N1 was
compiled that includes one X-ray apo-structure, one X-ray
holo-structure and 10 representative snapshots from the MD
simulation with the apo enzyme structure. The simulations
(previously reported; Grienke et al., 2010) were run as full
atom, explicit solvent MD simulations, and the representative
conformations were extracted by clustering the conformations
observed for a 20 ns trajectory of the production phase.
Subsequently, the NCI DTP’s compound library of ∼140,000
compounds was screened in silico with the docking software
GOLD. For the purpose of virtual screening and hit selection,
each of the 12models was treated as individual target.We visually
inspected the top-250 molecules of the individual hit lists and
selected a total of 108 compounds that we deemed potentially
active. GoldScore ranked all of the selected molecules among
the top-30 positions of the individual hit lists. We ordered a
subset of 80 compounds (prioritized by visual inspection) for
biological evaluation. Of these, 73 compounds passed the purity
and identity checks.
Biological Evaluation of Compounds with
Fluorescence-Based In vitro Assays
The compounds were screened with a fluorescence-based in vitro
assay on at least one influenza virus NA (i.e., A/Jena/5258/2009,
A/Jena/8178/2009 or A/WSN/1933) and NA from S. pneumoniae
strain DSM20566. Oseltamivir served as the control for the
FL assay for which the measured IC50 values were between
0.3 and 3 nM for the various viral NAs and roughly 1 µM for
NanA (Table 1). These values are in accordance with previously
published data (Richter et al., 2015; Walther et al., 2015; Xu
et al., 2016). Many of the compounds under investigation
caused strong assay interferences, e.g., via self-fluorescence
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TABLE 1 | Inhibition of IAV and S. pneumoniae NA in FL and HA assay.
Cpd Code (NSC) NA inhibition using FL assaya NA inhibition using HA assaya
IC50 (µM) MIC (µM)
IAV 8178/09 IAV WSN/33 IAV HK/68 S. p. DSM20566 IAV 5258/09 S. p. DSM20566
1 65847 1.40 ± 0.39 0.44 ± 0.10 1.42 ± 0.44 0.32 ± 0.05 10.00 ± 0.00 7.26 ± 3.75
2 73416 Not active 20.73 ± 2.59 83.02 ± 5.67 1.85 ± 0.10 Not activec 10.00 ± 0.00
3 65545 Not active Not active Not active 11.62 ± 0.15 Not activec Not activec
4 65557 84.27 ± 7.00 Not active 71.10 ± 22.01 4.79 ± 1.31 Not activec Not activec
5 45601 16.00 ± 5.05 6.70 ± 0.43 17.79 ± 3.25 0.97 ± 0.30 10.00 ± 0.00 2.44 ± 1.25
6 65826 Not active 36.40 ± 4.20 83.45 ± 3.67 1.18 ± 0.55 24.40 ± 12.47 Not activec
7 65551 65.40 ± 24.22 4.25 ± 1.25 87.17 ± 8.03 5.60 ± 3.01 Not activec Not activec
8 65553 Not active 6.51 ± 0.72 Not active 3.90 ± 0.51 Not active Not active
9 58050 Not active 22.66 ± 2.91 Not active 31.96 ± 10.92 Not active Not active
10 75953 Not active Not active Not active 10.18 ± 1.35 Not activec Not activec
11 45538 Not active 33.07 ± 4.60 77.26 ± 10.57 23.19 ± 13.12 Not active Not active
12 45540 Not active Not active Not active Not active Not active Not active
13 45541 Not active Not active Not active Not active Not active Not active
14 45576 Not active 28.92 ± 6.90 83.02 ± 6.25 5.74 ± 1.41 Not activec Not activec
15 75957 Not active 28.73 ± 3.30 Not active 46.79 ± 5.27 Not activec Not activec
16 45582 92.27 ± 10.01 44.27 ± 2.38 Not active 7.68 ± 0.98 31.60 ± 0.00 24.40 ± 12.47
17 45549 Not active Not active Not active Not active Not active Not active
Osel 0.003 ± 0.002 0.002 ± 0.001 0.0003 ± 0.0001 1.12 ± 0.32b 0.0007 ± 0.0004b 2.08 ± 1.25b
aMean and standard deviations of at least three independent experiments are shown.
bFor comparison data published by Richter et al. (2015) were included here.
cNot active at concentrations that either did not provoke hemagglutination or prevented virus-induced hemagglutination of human erythrocytes at certain concentrations (Supplementary
Table 1).
and fluorescence quenching, which affect FL assay results
(results not shown) (Kongkamnerd et al., 2011; Chamni
and De-Eknamkul, 2013; Richter et al., 2015). No significant
inhibitory activity on influenza virus NA was observed for
any of the tested compounds. However, for a diazenylaryl
sulfonic acid (3), we were able to reliably detect and confirm
biological activity against S. pneumoniae NA (IC50 = 11.62 µM;
Table 1). We ordered analogs of 3 from the same source and
characterized a total of 17 diazenylaryl sulfonic acids for which
reliable assay results could be obtained (Figure 1 and Table 1).
The most active compound, 7-[2-[4-[2-[4-[2-(2-hydroxy-3,6-
disulfo-1-naphthalenyl)diazenyl]-2-methylphenyl]diazenyl]-
2-methylphenyl]diazenyl]-1,3-naphthalenedisulfonic acid
(NSC65847; 1), had a measured IC50 < 1.5 µM for all of the
three tested viral NAs and NanA. Three further compounds
(5, 7, 8) inhibited the NA of WSN/33 with IC50 < 7 µM in
addition to a distinct inhibition of the bacterial NA. In total,
nine compounds (1, 2, 4–8, 14, and 16) showed IC50 < 8 µM
on S. pneumoniae NA. Among them is 14, which Amaro et al.
(2009) reported earlier as a weak inhibitor of influenza NA. We
confirmed a weak activity for two of the three tested viruses.
The low K i values determined by a series of substrate-velocity
curves against WSN/33 NA-wt (∼0.6 µM) and pneumococcal
NAs (0.11–0.19 µM) confirmed 1 as potential dual-acting NAI
(Table 2). Significant differences in the measured K i values were
observed between the constructs including the lectin domain
of NanA [9400_LC vs. 8919_LC (p = 0.016), and 9400_LC vs.
20566_LC (p= 0.024)]. In contrast, the construct consisting only
of the catalytic domain (CC construct) was inhibited with equal
effectiveness (K i = 0.16µM). The same trend was observed when
testing DANA, a transition state analog inhibitor of influenza
virus neuraminidase, albeit at higher concentrations (Xu et al.,
2016).
Confirmation of Biological Activity with a
Hemagglutination NA Inhibition Assay
An attempt was made to confirm the activity of these compounds
under neutral pH and with cell surface sialic acids in the
HA assay with human erythrocytes (Richter et al., 2015).
Unfortunately, several of the tested compounds (i.e., 3, 4, 6,
7, 10, 14, and 15) induced hemagglutination (Supplementary
Table 1), rendering these compounds non-evaluable at certain
concentrations in this cell-based NA inhibition assay. A further
phenomenon observed was the inhibition of viral hemagglutinin-
induced hemagglutination of human erythrocytes at 4◦C by 2
and 5 using concentrations between 31.6–100 µM and 3.16–
100 µM, respectively (Supplementary Table 1). Obviously, these
compounds either bind to the surface of human erythrocytes
or interfere with the viral hemagglutinin-sialic acid interaction.
As in the FL assay, the strongest activities were measured for
1 (Table 1), which exhibited none of the aforementioned assay
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FIGURE 1 | Overview of the diazenylaryl sulfonic acids investigated in this work.
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TABLE 2 | Km values for neuraminidases and MUNANA and Ki of 1.
Neuraminidases Compound 1 Binding
mechanism
Km* Ki (µM)*
S. pneumoniae
recombinant NanAs
8919_LC 18.01 ± 2.39 0.11 ± 0.02 Mixed
20566_LC 17.92 ± 2.12 0.12 ± 0.01 Mixed
20566_CC 20.20 ± 4.74 0.16 ± 0.03 Mixed
9400_LC 46.16 ± 1.71 0.19 ± 0.02 Mixed
9400_CC 46.39 ± 3.93 0.16 ± 0.01 Mixed
Influenza virus
A/WSN/33
without
preincubation
40.00 ± 3.86 0.60 ± 0.06 Mixed
20 min
preincubation
44.17 ± 4.63 0.60 ± 0.17 Mixed
*With the exception of Influenza virus A/WSN/33 without preincubation (n = 2), means
and standard deviations of at least 3 assays are shown.
interferences. The trend for compounds to be more active on
bacterial NA as observed with the FL assay was also confirmed
with the HA assay.
Inhibition Profile of Diazenylaryl Sulfonic
Acids in Influenza Virus Mutants
Six WSN/33 variants and wild-type (WT) virus generated via
reverse genetics (Schade et al., 2014; Hoffmann et al., 2016)
were used as a toolkit to examine the NA inhibition profile of
diazenylaryl sulfonic acids in the FL assay. The highly active
and virus-specific oseltamivir as well as the moderately active
DANA with broad-spectrum activity were included as control
compounds and studied for comparison. The inhibitory effect
of the tested compounds was affected only very little by amino
acid substitutions that confer resistance to oseltamivir (Table 3).
However, H274Y led to a significant impairment in the activity
of 1 as compared to the wild-type viral NA. A significant loss
in activity was also observed for 5 when tested on WSN/33
NA variants carrying the H274Y, N294S, Q136L, or I427Q/M
substitutions as compared to WSN/33 NA-WT. Surprisingly,
Y155H led to a five-times decreased IC50 value for 2, suggesting
stronger binding to this mutant. The inhibitory effect of DANA
was also affected only very little, but its inhibition profile differed
from that of the diazenylaryl sulfonic acids.
Cytotoxicity, Antiviral, and
Antipneumococcal Activity
Cytotoxicity was ruled out for all compounds for concentrations
up to 100 µM (Table 4). Six compounds (1–4, 6, and 7) inhibited
the 8178/09-, WSN/33-, or HK/68-induced cytopathic effect at
IC50 < 15 µM. As we reported recently, NanA supports the
spread and yield of 8178/09 in A549 cells (Walther et al., 2016b).
Treatment with 10 µM of 1 significantly inhibited virus yield
in both the absence and presence of NanA, underlining its dual
activity (Figure 2 and Supplementary Table 2).
The six antiviral compounds significantly reduced the
planktonic growth of S. pneumoniae (Table 4). Confirmation of TA
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TABLE 4 | Cytotoxicity, antiviral, and antibacterial activity of studied compounds.
Cpd. CC50 (µM) 50% inhibitory concentration and standard deviation (µM)
a
influenza A virus S. pneumoniae DSM20566b
8178/09 WSN/33 HK/68 Planktonic growth Biofilm formation
1 >100 20.36 ± 2.51 7.17 ± 0.96 18.50 ± 9.59 28.75 ± 13.13 49%b
2 >100 9.09 ± 1.94 11.83 ± 3.19 6.19 ± 4.62 4.59 ± 2.45 47%b
3 >100 14.42 ± 8.16 52.20 ± 17.91 13.63 ± 3.18 20.14 ± 2.24 Not active
4 >100 12.10 ± 4.83 13.96 ± 2.68 13.19 ± 3.11 11.97 ± 6.81 46%b
5 >100 Not active Not active Not active Not active 42.23 ± 2.57
6 >100 10.58 ± 0.71 24.22 ± 9.78 20.82 ± 1.99 6.14 ± 0.61 46%b
7 >100 3.28 ± 2.19 78.63 ± 16.18 4.22 ± 0.98 3.32 ± 0.72 46%b
8 >100 Not active Not active Not active Not active Not active
9 >100 Not active Not active Not active Not active Not active
10 >100 Not active Not active Not active Not active Not active
11 >100 Not active Not active Not active Not active Not active
12 >100 Not active Not active Not active Not active Not active
13 >100 Not active Not active Not active Not active Not active
14 >100 Not active Not active Not active Not active Not active
15 >100 Not active Not active Not active Not active Not active
16 >100 Not active Not active Not active 11.97 ± 6.81 46%b
17 >100 Not active Not active Not active Not active Not active
Oseltamivir 0.034 ± 0.022 0.009 ± 0.003 0.003 ± 0.001 Not studiedc Not studiedc
aAt least three independent assays were used to calculate mean and standard deviation in the cytopathic effect inhibition assays in MDCK cells. The maximum tested concentration in
the cytopathic effect inhibition and antibacterial assays was 100 and 50 µM, respectively.
b Inhibition of pneumococci activity at the maximum tested concentration of 50 µM.
cNot studied as control because confirmed as inactive (Walther et al., 2015).
FIGURE 2 | Recombinant pneumococcal NA (NanA) does not reduce
the inhibitory effect of 1 on virus yield. Influenza virus A/Jena/8178/09
(Jena/8178)-infected A549 cells (MOI of 0.1 TCID50/cells) were treated with
10 µM of 1 in the absence or presence of NanA. Virus titers in pfu/mL were
determined with plaque assay 48 h after infection. Virus control titer was set to
100% and inhibition of the control titer by NAI in % was calculated.
Experiments were performed twice with two parallels. Results of one
representative assay are shown exemplarily. Exact numbers of plaque-forming
units are reported in Supplementary Table 2.
bacterial viability on blood agar plates revealed a bacteriostatic
inhibition effect of the compounds (Supplementary Table 3).
The biofilm formation was not or was only slightly affected
(Table 4).
Compound 1 Abrogates Virus Infectivity
The effects of 1 on the cell-free virus and different stages of
the viral life cycle were evaluated and compared to that of
oseltamivir (Figure 3). MDCK cells were treated with oseltamivir
or 1 for 30 min at 37◦C. The unbound compound fraction
was removed by three washing steps before the addition of
virus. Plaque numbers were not affected by pretreatment with
oseltamivir or 1. Surprisingly, pretreatment of the cell-free virus
with 1 for 30 min at 37◦C (compound dilution to no-effect
concentrations before virus addition to MDCK cells) caused a
∼95% reduction of plaque number. Oseltamivir was not active
under these experimental conditions. It was also inactive when
added during the 2 h of virus adsorption on MDCK cells at 4◦C.
In contrast, addition of 1 reduced the number of plaques by 50%
during viral adsorption. When administering oseltamivir or 1 in
the agar overlay after virus adsorption, the percentage of plaque
reduction was enhanced. Administration of both compounds
during the whole replication cycle (during and after adsorption)
decreased plaque formation by up to 100%. Oseltamivir but not
1 strongly reduced the plaque size (Supplementary Figure 3).
DISCUSSION
The starting point of this work was the search for new inhibitors
of viral NAs. During the course of the study we found that
several diazenylaryl sulfonic acids picked up by virtual screening
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FIGURE 3 | Modified plaque reduction assay with (A) 1 µM of oseltamivir and (B) 100 µM of 1. “#” indicates a slight (plaques are half as large compared to the
virus control) and “##” a strong (plaques have about 10% of the size of the virus control) plaque size reduction. Bars represent the mean values and SD of at least
three experiments, each with two parallels per concentration. Images documenting the observed plaque size reduction are provided in Supplementary Figure 3.
inhibited S. pneumoniae NA in vitro and that some analogs
exhibited dual activity on viral and bacterial NAs.
Diazenylaryl sulfonic acids have been previously investigated
in the context of influenza NA inhibition. For example, in Becht
and Drzeniek (1968) reported on the inhibitory activity of the
azo dyes congo red and trypan red against myxovirus NA (and
viral replication), which they linked to a polyanionic effect.
Shortly thereafter, Akerfeldt (Akerfeldt et al., 1971) reported
on the antiviral (in particular also anti-influenza) activity of a
larger collection of aromatic sulfonic acids. It was suggested
that these compounds might be absorbed by the virions, thus
blocking virus entry into the host cells. Diazenylaryl sulfonic
acids also appear in the more recent literature, such as in the
report of Cheng et al. (2008) of a virtual screening campaign on
influenza NA using multiple structural models to represent the
conformational flexibility of the target protein and in a related
patent application (Amaro et al., 2009). With remazol brilliant
blue R (an anthraquinone dye), a further compound with an
aryl sulfonic acid scaffold was recently reported as an inhibitor
of influenza virus NA (Hsu et al., 2013). To the best of our
knowledge, there have been no reports of systematic efforts to
characterize the activity of these compounds yet.
The compounds investigated in the current study contain
substructures that have been associated with pan-assay
interference (Baell and Holloway, 2010). Therefore, extra
care was taken when conducting assays and interpreting their
readouts. However, the presence of an azenylaryl acid structure
in several established and well-tolerated aminosalicylate drugs
(e.g., sulfasalazine and olsalazine), used for the treatment
of chronic inflammatory diseases, demonstrates that the
diazenylaryl scaffold could serve as a valid starting point for
drug development. Intrigued by the reoccurring reports on
(diazenylaryl) sulfonic acids inhibiting influenza virus NA in
absence of conclusive evidence regarding their mode of action
and the fact that our screening campaign also picked up this type
of compound, we decided to investigate this phenomenon in
detail.
The data compiled during this study indicate that diazenylaryl
sulfonic acids can target influenza virus NA and S. pneumoniae
NanA. Assay interference in NA inhibition assays was carefully
ruled out by the concerted use of control measurements
e.g., self-fluorescence, quenching of fluorescence and self-
hemagglutination. Moreover, two different assays (FL and HA
assays) as well asWSN33NAs with single amino acids substituted
in proximity of the active site and different recombinant
pneumococcal NAs were used to confirm NA inhibition.
Whereas, the FL assay is performed with the synthetic substrate
MUNANA at acid pH, the HA assay allows testing of NA
inhibition under more physiological conditions (cleavage of cell
surface sialic acid at neutral pH) (Richter et al., 2015). The FL
assay showed an inhibition potential of diazenylaryl sulfonic
acids sensitive to the NA context: Activity of diazenylaryl sulfonic
acids tended to be higher on bacterial NanA (corresponding to
lower IC50 andKi values) as compared to viral NAs. The bioactive
chemical space of diazenylaryl sulfonic acids seems to be well
defined and narrow for viral NAs but broad for pneumococcal
NAs. The four compounds that inhibited at least one of the three
tested viral NAs and pneumococcal NA all comprise one (5,
7, 8) or two (1) additional diazenylaryl units linked with their
diazenylaryl sulfonic acid core. Compound 1 can be regarded
as a dimer-like analog of the initial hit, 3. None of the eight
tested compounds that consist of a single diazenylaryl unit were
active against viral NA but three of them were active against
pneumococcal NA (10, 14, and 16). Thus, the dual activity toward
both pneumococcal and viral NA seems to be associated with the
diazenylaryl sulfonic acid core in combination with at least one
additional diazenylaryl moiety. Unfortunately, only a minority of
the tested diazenylaryl sulfonic acids was evaluable with the HA
assay due to assay interferences. However, the obtained data fully
confirm NA inhibition for oseltamivir and the two most active
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compounds, 1 and 5. In addition, some significant differences in
the inhibitory activity of compounds were observed against the
mutated WSN/33 NAs (Table 3). The amino acid substitutions
did not result in changes in IC50 values as large as the change
observed for oseltamivir in the context of the H274Y mutation
but were in a range comparable to that of DANA (although the
pattern was different; Table 3).
The ligand binding sites of NAs have a highly polar character,
with a large number of charged amino acids, such as arginines
present. All approved NAIs comprise a carboxylic acid function
that forms a salt bridge with R371. It is plausible that the sulfonic
acid moiety that is present in all compounds under investigation
could mimic this interaction. However, deriving the potential
binding mode of diazenylaryl sulfonic acids proved difficult.
Automated ligand docking using the X-ray structural models and
the representative frames extracted from the MD trajectory did
not consistently point to a specific ligand orientation. Manual
docking of 5 into the substrate binding site of N1 NA resulted
in a docking pose which we consider plausible because of good
compatibility of chemical features and the molecular surfaces
with the open and closed conformations observed in crystal
structures (the open conformation is visualized in Figure 4).
However, this binding mode does not explain the activity of 5
FIGURE 4 | Potential binding mode of 5 (green carbon atoms) to N1
neuraminidase [Protein Data Bank (PDB) 2hu0]. Oseltamivir is depicted in
ball-and-stick mode with orange carbon atoms. In the proposed binding
mode, the sulfonic acid and phenolic moieties of 5 are oriented toward the
positively charged R118, R224, R292, and R371, hence forming ionic
interactions and a tight network of hydrogen bonds. The compound fits well to
the molecular shape of the ligand interaction site. Hydrophobic surface
contacts are formed, e.g., between the ligand’s terminal phenyl moiety and
I427 and K432.
on pneumococcal NA. Apparently, this compound does not fit
into the binding pocket of pneumococcal NA in this or a similar
orientation (data not shown). Additionally, for the other three
compounds active on viral NA (i.e., 1, 7, and 8) we were unable
to come up with a consistent and plausible binding mode. One
reason could be the remarkable flexibility of NAs that include
the regions of the binding site (Russell et al., 2006; Amaro et al.,
2007, 2009; von Grafenstein et al., 2013). On the other hand,
the inconsistent results suggest that this type of compound most
likely binds in different orientations to the substrate binding
site that are defined by ionic interactions with the active site
arginines.
Enzyme kinetics experiments were conducted to investigate
the binding mechanism of 1 (Table 2). Nonlinear regression
and curve fitting modeled by SigmaPlot suggested a mixed-
type inhibition for this compound on viral NA and all NanA
constructs (Supplementary Figures 1, 2). Mixed-type inhibition
indicates that the formation of the enzyme-substrate complex
is inhibited as well as the turnover in case an enzyme-substrate
complex is formed. Pre-incubation of viral NA with the inhibitor
did not lead to lower K i values, suggesting that 1 binds rapidly
to the target. Thus, in contrast to approved NAIs (Barrett et al.,
2011), 1 represents a fast-binding inhibitor. However, the fact
that the intersection point of the different concentrations in the
Lineweaver-Burk plots (Supplementary Figures 1, 2) is above the
x-axis can be understood to mean that the affinity to the enzyme
is higher than to the enzyme substrate complex. Thus, the results
from the enzyme kinetics experiments are in agreement with the
hypothesis that diazenylaryl sulfonic acids directly interact with
the positively charged substrate binding site.
The importance of the ionic interaction is partially reflected
in the structure-activity relationship of the compounds. The
most active compound, 1, also contains the highest number of
sulfonic acid groups (i.e., four). Compound 5 differs from 4
by only one additional sulfonic acid group and is more active.
However, also 8 differs from 7 by only one additional sulfonic
acid group, and the activities of both compounds on viral and
bacterial NA are comparable. Thus, the relationship between the
number of charged groups (i.e., sulfonic acids) and activity on
viral or pneumococcal NA is not consistent. Also, the presence of
a sulfonic acid group is not sufficient for the biological activity
of the investigated diazenylaryl sulfonic acids. For example, 9
contains three sulfonic acid groups and showed no or very low
activity on any of the tested NAs.
Care must be taken during the quantitative interpretation
of cell-based antiviral assays (Table 4). In general, IC50 values
are expected to be higher for these more complex assays.
Against expectation, compounds 4 and 7 showed an inhibition
of the cytopathic effect (CPE) at concentrations that did not
effectively inhibit neuraminidase activity. Similarly, 2 and 3
inhibited the CPE of two investigated influenza viruses with
<15 µM concentration (Table 4), while NA activity was not
inhibited at concentrations up to 100 µM or inhibited by
50% at higher concentrations, respectively (Table 1). Several azo
compounds adhere to erythrocytes (as seen in the experimental
controls of the HA assay; Supplementary Table 1), which can
be disadvantageous for drug discovery. Taken together, these
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observations indicate that a further mechanism could be involved
in mediating the anti-influenza activity of some diazenylaryl
sulfonic acids.
The potent dual activity of 1 could be shown in NA
inhibition assays as well as cellular experiments in the
presence of virus and exogenous NanA (Figure 2), wherein the
synergistic effect of the pneumococcal co-infection is simulated
(McCullers and Bartmess, 2003). Given its good antiviral and
antipneumococcal activity, its favorable cell compatibility, and
the absence of hemagglutination, compound 1 could serve
as an interesting starting point for the development of dual-
acting NAIs. We recently identified such a dual inhibition
mode for isoprenylated natural compounds including artocarpin,
sanggenol A and congeners of sanggenol A (Walther et al.,
2015; Grienke et al., 2016). Like diazenylaryl sulfonic acids,
these natural compounds exert a stronger inhibitory effect on
pneumococcal as compared to viral NA. However, some of the
diazenylaryl sulfonic acids are stronger inhibitors of viral NA
and viral replication than the natural compounds. In contrast,
their antibacterial effect is weaker and bacteriostatic, whereas
artocarpin, sanggenol A and its congeners act bactericidal and
kill S. pneumoniae.
The strong effect of 1 on plaque formation (Figure 3) upon
pretreatment of the virus is an indication that the activity of
diazenylaryl sulfonic acids goes beyond that of the substrate-
analogous inhibitors.
In summary, we characterized 17 diazenylaryl sulfonic
acids regarding their anti-NA, antiviral and antibacterial
activity, and cytotoxicity. Compound 1 unfolded as the most
active compound, with K i values <1.5 µM (FL assay) for
both viral and pneumococcal NAs. It showed antiviral and
antipneumococcal activity, and hence could serve as a starting
point for the development of novel, dual-acting anti-infectives.
All observations made with in silico and in vitro methods
point toward diazenylaryl sulfonic acids binding to viral and
pneumococcal NAs not in a purely competitive manner but in
a mixed mode. A major component of activity can be ascribed to
specific interaction with NAs, as evidenced by distinct bioactivity
patterns observed for viral and pneumococcal NAs.
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